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Abstract: We produced low-molecular-weight heparin/protamine nanoparticles (LMW-H/P 
NPs) as a carrier for heparin-binding growth factors, such as fibroblast growth factor-2 (FGF-2). 
A mixture of low-molecular-weight heparin (MW: about 5000 Da, 6.4 mg/mL) and protamine 
(MW: about 3000 Da, 10 mg/mL) at a ratio of 7:3 (vol:vol) yields a dispersion of microparticles 
(1–6 µm in diameter). In this study, diluted low-molecular-weight heparin solution in saline 
(0.32 mg/mL) mixed with diluted protamine (0.5 mg/mL) at a ratio at 7:3 (vol:vol) resulted in 
soluble nanoparticles (112.5 ± 46.1 nm in diameter). The generated NPs could be then stabilized 
by adding 2 mg/mL dextran (MW: 178-217 kDa) and remained soluble after lyophilization of 
dialyzed LMW-H/P NP solution. We then evaluated the capacity of LMW-H/P NPs to protect 
activity of FGF-2. Interaction between FGF-2 and LMW-H/P NPs substantially prolonged the 
biological half-life of FGF-2. Furthermore, FGF-2 molecules were protected from inactivation 
by heat and proteolysis in the presence of LMW-H/P NPs.
Keywords: polyelectrolyte complexes, nanoparticles, fibroblast growth factor-2, drug carrier
Introduction
Polyelectrolyte complexes (PECs) are the products of electrostatic interaction 
between oppositely charged polyelectrolytes. Nonstoichiometric PECs are composed 
of oppositely charged polyions taken in nonequivalent ratios. As a result, each PEC 
particle carries an excess charge.1,2 PECs are convenient models for studying the 
in vivo behavior of charged biopolymers. The attractive combination of a simple 
preparation procedure and unique properties offer various possible applications 
of PECs in medicine and biotechnology.3,4 Proteins interact with both synthetic 
and natural polyelectrolytes.5,6 Some evidences exist for the binding of polyanions 
and polycations to proteins below and above their isoelectric points, respectively. 
These interactions can result in soluble complexes, complex coacervation and/or the 
formation of amorphous precipitates.4–6 Main aspects studied by different authors 
are compositions of PECs obtained under various experimental conditions, such 
as the strength and position of ionic sites, charge density, and rigidity of polymer 
chains, as well as chemical properties such as solubility, pH, temperature, and 
concentration.1–4
An interest in such electrostatic interactions lies in their similarity to biological 
systems; 7 such interactions between proteins and nucleic acids very likely play 
a role in the transcription process.5 DNA/chitosan PECs,8 chiosan/chondroitin 
sulfate PECs and chitosan/hyaluronate PECs9 have been reported as gene and International Journal of Nanomedicine 2010:5 148
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drug carriers. Moreover, PECs which are insoluble, also 
have potential applications as, for example, membranes, 
microcapsules, micro (nano)-particles and scaffolds for 
tissue engineering.10
Heparinoids are known to specifically interact with variety 
of functional proteins, including growth factors, cytokines, 
extracellular matrix components and adhesion molecules.11–13 
Thus, heparin may be useful as a therapeutic agent in vari-
ous pathological conditions involving functional proteins. 
However, high-dose heparin cannot be used because of the 
excessive risk of bleeding.14 In contrast, low-molecular-weight 
heparin (LMW-H, MW: about 5000 Da) has pharmacological 
and practical advantages when compared with heparin. The 
lower protein binding activity of LMW-H produces a low, 
stable and predictable anticoagulant response, thereby obviat-
ing the need for laboratory monitoring to adjust the dosage.14 
In addition, one or two subcutaneous injections per day are 
sufficient to maintain therapeutic concentrations, due to its 
longer plasma half-life.14
On the other hand, protamine, a purified mixture of 
proteins obtained from fish sperm, neutralizes heparin and 
LMW-H by forming a stable complex that lacks anticoagu-
lant activity.15 Protamine is also in clinical use to reverse the 
anticoagulant activity of heparin following cardiopulmo-
nary bypass and in cases of heparin-induced bleeding.16 We 
previously prepared water-insoluble particles (10 µm in 
diameter) by mixing nonanticoagulant heparin and chitosan 
and by mixing of fucoidan and chitosan, and investigated 
the capacity of the resulting insoluble fucoidan/chitosan 
microparticles to protect activity of fibroblast growth factor-2 
(FGF-2).17,18 We also prepared water-insoluble microparticles 
(1 µm in diameter) by mixing LMW-H (6.4 mg/mL) 
and protamine (10 mg/mL) at a ratio of 7:3 (vol:vol), and 
investigated the capacity of the resulting injectable LMW-
H/protamine microparticles (LMW-H/P MPs) to protect the 
activity of FGF-2.19 However, after the LMW-H/P MPs were 
freeze-dried, a cotton-like amorphous material was generated, 
and this was not dissolved with water. In this study, we used 
diluted LMW-H (0.32 mg/ml) as an anion molecule and the 
diluted protamine as a cation molecule to synthesize LMW-
H/protamine nanoparticles (LMW-H/P NPs; about 120 nm 
in diameter). Although the LMW-H/P NPs were also freeze-
dried, cotton-like amorphous materials were generated, and 
these were not dissolved with water, the generated LMW-H/P 
NPs as well as LMW-H/P MPs were then stabilized by add-
ing dextran. Here, we report that LMW-H/P NPs are able to 
interact with FGF-2 and to protect FGF-2 activity from heat 
and proteolytic inactivation.
Material and methods
Preparation of LMW-h/P NPs  
and LMW-h/P MPs
LMW-H/P MPs were prepared as reported elsewhere.19 
Briefly, 0.3 mL of protamine solution (10 mg/mL; Mochida 
Pharmaceutical Co., Ltd., Tokyo, Japan) was drop by drop 
added to 0.7 mL of LMW-H solution (Fragmin®, 6.4 mg/mL; 
Kissei Pharmaceutical Co., Ltd., Nagano, Japan) with vortex-
ing for approximately 2 min. To maximize the production of 
microparticles, LMW-H and protamine were mixed at a ratio 
at 7:3 (vol:vol). The solution of LMW-H/P MPs (1 mL) was 
then subjected to washing twice with phosphate-buffered 
saline (PBS) to remove unreacted materials, and was made up 
with 1 ml of PBS. More than 7 mg of freeze-dried LMW-H/P 
MPs was obtained from 1 ml of the LMW-H/P MP solution, 
and the dried LMW-H/P MPs were substantially aggregated 
and insoluble cotton-like materials were generated in the re-
suspended freeze-dried LMW-H/P MPs. However, addition 
of 5 mg/mL dextran prevented such aggregation.
In order to prepare LMW-H/P NPs, 30 ml of 20-fold 
diluted protamine solution (0.50 mg/ml) in saline (Otsuka 
Pharmaceutical Co. Ltd., Tokyo, Japan) was drop by 
drop added to 70 ml of 20-fold diluted LMW-H solution 
(0.32 mg/ml) in saline with stirring. The solution (100 ml) 
was mixed with 200 mg of dextran (MW: 178–217 kDa; MRC 
Polysaccharide Corp., Tokyo, Japan) and was then dialyzed 
for 3 days against distilled water using a dialysis membrane 
(Seamless Cellulose Tubing; Fractional molecular weight: 
12–14 kDa; Sanko Corp., Tokyo, Japan) in order to remove 
unreacted materials and salts, and the dialysate was lyophi-
lized. The weight of lyophilized powder was 239 mg including 
200 mg of dextran and the produced powder was resuspended 
in 20 ml of PBS. Particle aggregation with addition of dex-
tran was not observed, even in re-suspended freeze-dried 
LMW-H/P NP solution. As the concentration of LMW-H in 
the LMW-H /P NP solution was 0.82 mg/mL according to a 
sulfated glycosaminoglycan assay kit (BlyscanTM; Biocolor 
Ltd., Newtownabbey, North Ireland), it was estimated that 
about 73% of LMW-H was converted into LMW-H/P NPs. 
If 100% of protamine was converted to LMW-H/P NPs, 
the final yield of LMW-H/P NPs was about 31.4 mg in the 
20 mL of LMW-H/P NP solution. In order to prepare stock 
solution for FGF-2 protection, 10 µL of 1.0 mg/mL FGF-2 
(Fiblast; Kaken Pharmaceutical Corp., Tokyo, Japan) in 
PBS (final concentration of FGF-2: 10 µg/mL) was then 
added to 1 mL of the resuspended freeze-dried LMW-H/P 
NP (3.14 mg/mL) and dextran (20 mg/mL) solution with International Journal of Nanomedicine 2010:5 149
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medium-199 (Life Technologies Oriental Corp., Tokyo, 
Japan) containing antibiotics and lacking heat-inactivated 
fetal bovine serum (FBS) on ice, followed by vortexing.
scanning electron microscopy (seM)
SEM was carried out using a JEOL JSM-6340F (JEOL Ltd., 
Tokyo, Japan) at 5 kV . SEM specimens of LMW-H/P NPs 
(LMW-H/P MPs) were prepared by coating a cover glass with 
a drop of 5 µL water dispersion of the perticles. The specimen 
was followed by gentle drying in a dry-box for overnight. To 
enhance conductivity of the specimen, osmium plasma coat-
ing was performed using the plasma multi-coater PMC-5000 
(Meiwafosis Co., Ltd., Tokyo, Japan) after drying. Particle 
size distributions of LMW-H/P NPs and LMW-H/P MPs were 
measured in SEM images using LabVIEW (Version 8.5) with 
the Vision Development/Module (National Instrument Co., 
Austin, TX, USA). To obtain the average size and standard 
deviation of the particles, each particle images on the SEM 
micrographs were evaluated as circle with LabVIEW and the 
diameters of the relevant circles were used for the calculation. 
The number of the particles used for the calculation was more 
than 400 (for NPs) or 100 (for MPs).
hMVec culture and protection of FgF-2 
from inactivation by LMW-h/P NPs
Human dermal micro-vascular endothelial cells (HMVECs; 
Takara Biochemical Corp., Ohtsu, Japan) were cultured in 
medium-199 supplemented with 10 wt% FBS, antibiotics 
(100 U/mL penicillin G and 100 µg/ml streptomycin) and 
5 ng/mL FGF-2. Those cells used in this work were all 
between the fourth and eighth cell cycle passage.
In order to study the effects of LMW-H/P NPs on inhi-
bition of FGF-2 inactivation with various incubation times, 
10 µg of FGF-2 was added to 1 mL of medium-199 (Life 
Technologies Oriental Corp., Tokyo, Japan) without FBS 
containing 3.14 mg/mL LMW-H/P NPs (with 20 mg/mL 
dextran), 1.6 mg/mL LMW-H or 20 mg/mL dextran, and these 
solutions were thoroughly mixed as stock solutions. Stock 
solutions were directly incubated at 37°C for the indicated 
periods. For heat treatment of FGF-2, 0.1 mL of each stock 
solution was heated at 37, 44, 51, 58, 65 and 72°C for 30 min. 
To study the effects of trypsinization of FGF-2, 0.1 mL of 
trypsin-EDTA solution (0.5 mg/mL trypsin, 0.2 mg/mL 
EDTA/4Na in HBSS; Sigma, St. Louis, MO, USA) was 
added to 0.1 mL of each chilled stock solution, followed by 
incubation at 37°C for the indicated periods. After incubation, 
0.1 mL of FBS was added to each trypsinized stock solution 
in order to stop the trypsinization reaction.
Those inactivated FGF-2 stock solutions were diluted 
with medium-199 supplemented with 10% FBS and antibiot-
ics at the indicated concentrations, and the media were used 
for HMVEC culture. The HMVECs were seeded at an initial 
density of 3 000 cells/well in 96-well tissue culture plates, 
and were grown for 3 days in 200 µL of one of the prepared 
media. After incubation, the medium used was removed and 
100 µL of fresh medium including 10 µL of WST-1 reagent 
(Cell counting kit, Dojindo, Kumamoto, Japan) was added 
to each well. Plates were read at 450 nm using a Mini Plate 
Reader (Nunc InterMed, Tokyo, Japan) after 1 h incubation 
at 37°C.
Results
Appearance and characteristics of LMW-
h/P MPs produced by mixing LMW-h 
and protamine at various ratios
When nondiluted protamine (10 mg/ml) was drop by drop 
added to nondiluted LMW-H (6.4 mg/mL) until 0.4 of the 
volume fraction, a gradual increase in turbidity was observed 
(Figure 1). Figure 2 shows that the high turbidity was due to 
the generated LMW-H/P MPs (2.93 ± 1.11 µm in diameter). 
Turbidity was measured by reading OD at 630 nm using a 
Mini Plate Reader (Nunc InterMed., Tokyo, Japan). When 
the volume fraction of protamine was low (0.10–0.15), 
the turbidity was also low. However, electron microscopic 
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Figure 1 changes in turbidity by mixing protamine to LMW-h at various ratios. 
When protamine (10 mg/mL) was added dropwise to LMW-h (6.4 mg/mL) until 
0.4 of the volume fraction, gradual increases in turbidity were observed. When the 
volume fraction of protamine was high (0.5), turbidity was very low due to gener-
ated insoluble oily precipitates.
Abbreviations: LMW-h, low-molecular-weight heparin.International Journal of Nanomedicine 2010:5 150
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observation confirmed the generation of LMW-H/P NPs 
(about 100 nm in diameter) and LMW-H/P MPs (about 
1 µm in diameter) (data not shown). Furthermore, when the 
volume fraction of protamine was high (0.5), insoluble oily 
precipitates were generated, and turbidity of the supernatant 
was almost zero (Figure 1). An illustration of the generation 
of micro/nanoparticles by mixing protamine (10 mg/mL) 
and LMW-H (6.4 mg/mL) at various volume ratios is shown 
in Figure 3. In contrast, when nondiluted LMW-H was 
drop by drop added to nondiluted protamine, insoluble oily 
precipitates were immediately generated. The reaction was 
irreversible, and the generation of micro/nanoparticles was 
not observed.
Appearance and characteristics of LMW-
h/P NPs produced by mixing LMW-h 
and protamine at various concentrations
In order to produce nanoparticles, equally diluted LMW-H 
and protamine (100-fold, 50-fold, and 20-fold diluted) were 
mixed at a ratio at 7:3 (vol:vol) (Figure 4). The diameters 
of LMW-H/P NPs generated by mixing 100-fold, 50-fold, 
and 20-fold diluted protamine to equally diluted LMW-H 
in a ratio of 3:7 (vol:vol) were 84.6 ± 26.8, 95.0 ± 27.0, 
and 112.5 ± 46.1 nm, respectively, and no microparticles 
(1 µm in diameter) were observed in these mixtures. In 
contrast, a certain amount of microparticles (about 1 µm 
in diameter) were observed when mixing 10-fold diluted 
protamine (1.0 mg/mL) with LMW-H (0.64 mg/mL) at a 
ratio of 3:7 (vol:vol). When nondiluted protamine (10 mg/
mL) was added to nondiluted LMW-H (6.4 mg/mL) at a 
ratio of 3:7 (vol:vol), maximal LMW-H/P MPs (2.93 ± 
1.11 µm in diameter) was produced and high turbidity 
was observed (Figure 1). When 10-fold concentrated 
protamine (100 mg/mL) was added to equally concentrated 
LMW-H (64 mg/mL) at a ratio of 3:7 (vol:vol), mixtures 
of LMW-H/P MPs and larger cotton-like precipitates were 
immediately generated and the products were insoluble 
(data not shown).
effects of dextran on resolubility  
after lyophilization
Cotton-like compounds were generated after lyophilization 
of both LMW-H/P NP and LMW-H/P MP solutions (without 
dextran), and these were hardly re-soluble in water. However, 
both the freeze-dried LMW-H/P MPs and LMW-H/P NPs 
were easily dissolved in water by adding 0.5% and 0.2% 
dextran, respectively, before lyophilization. In addition, 
aggregation of LMW-H/P NPs and LMW-H/P MPs in solu-
tion was prohibited in the presence of dextran. Thus, addition 
of dextran stabilizes the LMW-H/P NPs and LMW-H/P MPs 
in solution, and allows preparations of stable and resoluble 
freeze-dried LMW-H/P MPs and LMW-H/P NPs.
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Figure 2 LMW-h/P MPs produced by mixing protamine to LMW-h. LMW-h (6.4 mg/mL) 
and protamine (10 mg/mL) were mixed to produce LMW-h/P MPs at a ratio of 7:3 
(vol:vol). Produced microparticles were aggregates composed of many nanoparticles 
and particle size was 2.93 ± 1.11 µm.
Abbreviations: LMW-h, low-molecular-weight heparin; LMW-h/P, low-molecular-
weight heparin/protamine; MPs, microparticles.International Journal of Nanomedicine 2010:5 151
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Figure 3 Illustration of LMW-h/P MP and LMW-h/P NP generation by mixing protamine to LMW-h at various ratios.
Abbreviations: LMW-h, low-molecular-weight heparin; LMW-h/P, low-molecular-weight heparin/protamine; MP, microparticle; NP, nanoparticle.
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Figure 4 LMW-h/P NPs produced by mixing diluted protamine and LMW-h. equally diluted aqueous LMW-h solution and protamine solution were mixed at a ratio of 7:3 
(vol:vol) to produce LMW-h/P NPs. Produced nanoparticles were Pecs and nanoparticle size was 84.6 ± 26.8 and 95.0 ± 27.0 nm after mixing 100- and 50-fold diluted prot-
amine and LMW-h, respectively. When mixing 20-fold diluted protamine and LMW-h solutions, LMW-h/P NPs were generated and the size was 112.5 ± 46.1 nm.
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LMW-h/P NPs protect FgF-2  
from inactivation
When FGF-2 is incubated at 37°C for 1 day or more, its 
mitogenic activity is substantially reduced (90%), whereas 
no decrease in the mitogenic activity of FGF-2 was observed 
in the presence of either 1.6 mg/mL LMW-H with 20 mg/mL 
dextran, 3.14 mg/mL LMW-H/P NPs with 20 mg/mL dextran, 
or 20 mg/mL dextran alone for at least 7 days (Figure 5). The 
biological half-life of 10 ng/mL FGF-2 in the presence of 
LMW-H/P NPs with dextran, LMW-H with dextran, dextran 
and control (non) was approximately 7 days, 7 days, 
2 days, and 1 day, respectively.
Heparin protects FGF-2 from inactivating treatments 
by heat and proteolysis.19–21 To determine whether LMW-
H/P NPs with dextran could protect FGF-2 against heat 
inactivation, FGF-2 (10 µg/mL) was heated in the presence 
of LMW-H/P NPs (3.14 mg/mL). As shown in Figure 6, 
heat exposure at over 51°C in the absence of LMW-H with 
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Figure 5 Protective effects of LMW-h/P NP on FgF-2 activity. stock solutions (10 µg/ml FgF-2 with 3.14 mg/mL LMW-h/P NPs with 20 mg/mL dextran (●), 1.6 mg/mL 
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diluted to the indicated concentrations with culture medium. hMVecs were cultured for 3 days using one of the prepared media, and data represent means ± sD of quadru-
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dextran, dextran or LMW-H/P NPs with dextran resulted in 
more than 95% FGF-2 inactivation. Dextran (20 mg/mL) 
almost completely protected FGF-2 activity up to 51°C and 
partially protected it at 58°C and 65°C. On the other hand, 
LMW-H with dextran and LMW-H/P NPs with dextran 
showed greater protective effects against FGF-2 activity in 
heat treatment up to 65°C.
LMW-H with dextran, dextran, and LMW-H/P NPs with 
dextran were able to protect inactivation of FGF-2 after trypsin 
treatment, while activity was lost in controls (Figure 7). In the 
presence of trypsin, the biological half-life of 10 ng/mL FGF-
2 with LMW-H with dextran, dextran and LMW-H/P NPs 
with dextran was about 120 min, 80 min, and 120 min, 
respectively (with control (non) = 20 min). Thus, LMW-H/P 
NPs protects FGF-2 from inactivating treatments, similar to 
LMW-H/P MPs.19
Discussion
PECs are formed by electrostatic interactions between 
positively and negatively charged polymers.8 Basic prot-
amine molecules complexed with acidic molecules (eg, 
LMW-H) form microparticles through ionic interactions. 
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Figure 7 Protective effects of LMW-h/P NPs on bioactivity of trypsin-treated FgF-2. 
stock solutions (10 µg/mL FgF-2 with 3.14 mg/mL LMW-h/P NPs with 20 mg/mL 
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hMVecs were cultured for 3 days using one of the prepared media, and data represent 
means ± sD of quadruplicate determinations.
Abbreviations: FGF-2, fibroblast growth factor-2; HMVECs, human dermal micro-
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We previously reported FGF-2-containing LMW-H/P MPs, 
which are 2.93 ± 1.11 µm in diameter, and due to their size, 
FGF-2-containing LMW-H/P MPs can be easily injected.19 
FGF-2-containing LMW-H/P MPs showed substantial induc-
tion of vascularization and fibrous tissue formation due to 
the gradual release of FGF-2 molecules from LMW-H/P 
MPs.19 However, LMW-H/P MPs are unstable; the particles 
irreversibly fuse and become larger (10 µm in diameter) 
during long-term storage (1 week or longer). Furthermore, 
after LMW-H/P MPs are freeze-dried, cotton-like materi-
als are produced, and these do not dissolve in water. In 
this study, we established a method for preparing stable 
LMW-H/P NPs (about 100 nm in diameter), as well as 
stable LMW-H/P MPs (2.93 ± 1.11 µm in diameter), that 
maintained their solubility after lyophilization. Furthermore, 
the size of the generated particles (from about 100 nm to 
about 3 µm) could be controlled by dilution of the LMW-H 
and protamine solutions.
It is considered that whether LMW-H/P complexes 
form single nanoscale particles or microscale aggregates is 
dependent on concentrations of LMW-H and protamine in 
the pre-reaction solution.22 Polymer chains of both LMW-H 
and protamine have a number of reactive sites to counter-
molecules, and multiple polymer chains were involved in 
one LMW-H/P particle. Higher aggregation (MPs) was 
formed when higher concentration of both polymers was 
applied. The typical case derived from the high aggregation 
was observed in the mixture with nondiluted LMW-H and 
protamine. Because irreversible crosslinking simultaneously 
occurred between a large number of both LMW-H and 
protamine chains, strict size distribution of LMW-H/P MPs 
got out of control. Despite the difficulty of size distribution 
control of LMW-H/P MPs, it should be noted that any 
problems did not exist in the repeatability of the experi-
ments using LMW-H/P MPs studied to date.19 On the other 
hand, in 20-fold and more diluted systems, only nanoscale 
particles were formed. And SEM of 10-fold diluted system 
showed that the products were a mixture of aggregations 
(MPs) and NPs.
When nondiluted protamine (10 mg/ml) was added drop 
by drop to nondiluted LMW-H (6.4 mg/ml) at a ratio of 3:7 
(vol:vol), LMW-H/P MPs were generated (Figure 2). As 
described above, LMW-H/P MPs were stabilized by addition 
of 5 mg/mL dextran, and the freeze-dried powder of LMW-
H/P MPs and dextran easily dissolved in water, PBS and 
various culture media. Microscopic observations showed that 
the re-dissolved LMW-H/P MPs in solution were identical to 
those before lyophilization. Furthermore, FGF-2-containing 
LMW-H/P MPs stabilized with dextran showed the same 
induction of vascularization and fibrous tissue formation 
due to the gradual release of FGF-2 molecules, as reported 
previously.19
There are some advantages in nanoparticles (200 nm) 
as a drug carrier, as compared with microparticles (1 µm); 
(i) LMW-H/P NPs containing drugs may be administered 
intravenously, but LMW-H/P MPs may not, due to the 
higher risk of causing embolism by MPs because larger 
sizes of MPs are identical to that of red blood cells, the 
MPs are easily aggregated, and the MPs adhere to the wall 
of blood vessels, (ii) LMW-H/P NPs as a drug carrier may 
be endermically administered, but LMW-H/P MPs are too 
large,23,24 and (iii) LMW-H/P NPs diffuse into a relatively 
large area, but LMW-H/P MPs do not. Therefore, we 
tried to prepare stable LMW-H/P NPs in this study. When 
20-fold diluted protamine (0.5 mg/mL) was added drop 
by drop to 20-fold diluted LMW-H (0.32 mg/mL) at a 
ratio of 3:7 (vol:vol), LMW-H/P NPs (112.5 ± 46.5 nm in 
diameter) were generated (Figure 4), and no microparticles 
(1 µm in diameter) were observed in the mixture. The 
generated nanoparticles were also stabilized by adding 
dextran (2 mg/ml) and maintained their solubility after 
lyophilization.
FGF-2 is known to bind to heparin and LMW-H with 
high affinity (Kd of 8.6 × 10-9 M).18,25 The polysaccharides 
also prolong the biological half-life of FGF-2 activity, and 
protect FGF-2 from heat, acid and proteolytic inactivation at 
concentrations up to 3 µg/mL.18 LMW-H/P MPs also have a 
high affinity for FGF-2 (Kd = 2.4 × 10-9 M),19 and interaction 
between FGF-2 and LMW-H/P NPs substantially prolongs 
the biological half-life of FGF-2. LMW-H/P NPs also effec-
tively protected FGF-2 against heat inactivation and trypsin 
degradation. The results demonstrated that FGF-2 molecules 
interact with, and are stabilized by LMW-H/P NPs, and that 
the FGF-2 molecules incorporated into the LMW-H/P NPs 
would be gradually released upon diffusion and biodegrada-
tion of the nanoparticles in vivo.
Heparinoids, including heparin and LMW-H, are known 
to bind cytokines such as FGFs, hepatocyte growth fac-
tor (HGF), vascular endothelial growth factor (VEGF), 
heparin-binding epidermal growth factor (HBEGF), platelet-
derived growth factor (PDGF), transforming growth factor-β 
(TGF-β), GM-CSF, interleukins (ie, IL-1, IL-2, IL-3, IL-4, 
IL-6, IL-7, and IL-8), interferon-γ and macrophage inflam-
matory protein-1 (MIP-1).26,27 LMW-H/P NPs can therefore 
be applied to such heparin-binding cytokines as a nanocarrier 
for drug delivery.International Journal of Nanomedicine 2010:5
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Conclusion
In the present work, we established a methodology to prepare 
stable LMW-H/P NPs, and evaluated the effects of FGF-
2-containing LMW-H/P NPs on the protection of FGF-2 
activity from heat and proteolytic inactivation. The results 
presented in this study indicate that LMW-H/P NPs may 
serve as an effective nanocarrier for various heparin-binding 
cytokines, including FGF-2, particularly in the local applica-
tion of heparin-binding cytokines.
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